THE LAB — TRIM FITT CLINICAL RESEARCH
Tesamorelin: FDA-Approved Peptide for Fat Loss and Cognitive Health
Reviewed by the TRIM FITT Clinical Team · Evidence-Based Medicine
Tesamorelin stands apart from many peptides in one important way: it has received FDA approval. Originally developed and approved for the treatment of HIV-associated lipodystrophy (excess visceral fat caused by antiretroviral therapy), tesamorelin has since gained attention in the broader longevity and metabolic medicine space for its ability to reduce visceral adipose tissue and support cognitive function.
What the Research Shows
Tesamorelin is a stabilized analog of GHRH that stimulates the pituitary gland to release growth hormone. The pivotal LADI and PERI trials demonstrated significant reductions in visceral adipose tissue (VAT) in HIV-positive patients, with average reductions of 15-18% over 26 weeks. More recently, research from the Journal of Clinical Endocrinology and Metabolism and cognitive neuroscience studies have explored tesamorelin’s effects on brain health — finding improvements in verbal memory and reduced amyloid accumulation in older adults with mild cognitive impairment.
Bottom line: Tesamorelin is the only FDA-approved GHRH analog, backed by strong clinical evidence for visceral fat reduction and emerging evidence for neuroprotection and cognitive preservation.
What This Means at TRIM FITT
At TRIM FITT, every protocol is built on peer-reviewed evidence. Tesamorelin is available through our physician-supervised longevity protocols with appropriate metabolic monitoring. Book a consultation to find out which protocol is right for you.
Schedule Your TRIM FITT Consultation →
📚 Peer-Reviewed Sources
Educational purposes only. Not medical advice. Consult with a TRIM FITT provider before starting any treatment.
Ready to Start Your Protocol?
TRIM FITT is a physician-led telehealth practice offering personalized peptide therapy, GLP-1 weight loss programs, ketamine therapy, and more — delivered to your door.